Procizumab shows safety and tolerability in first-in-human trial for cardiogenic shock
Procizumab (PCZ) demonstrated mild adverse events and no serious safety concerns in Phase 1 trial with healthy volunteers.
Phase I
Cardiovascular / Monoclonal Antibody
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The positive safety profile of Procizumab in its first-in-human trial is significant as it may lead to a new treatment option for cardiogenic shock, a critical condition with limited effective therapies. Monitoring the ongoing PROCARD trial will be essential to assess its efficacy and potential market impact.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor outcomes from the PROCARD Phase 1b/2a trial for efficacy data and optimal dosing in patients with cardiogenic shock.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.